Hospital volume-outcome relationship in total knee arthroplasty: protocol for a systematic review and non-linear dose-response meta-analysis

Tanja Rombey1*, Käthe Goossen1, Jessica Breuing1, Tim Mathes1, Simone Hess1, Rene Burchard2,3 and Dawid Pieper1

Abstract

Background: Knee osteoarthritis is a common, chronic condition and main contributor to global disability. Total knee arthroplasty (TKA) is the most successful treatment for end-stage knee osteoarthritis. It is assumed that in the field of surgery, there is a relationship between hospital volume and health outcomes and that higher hospital volume results in better health outcomes. As a consequence, minimum volume thresholds have been implemented in Germany for various procedures, including TKA (50 procedures per year). To date, it is unclear whether minimum volume thresholds truly result in better outcomes. The objective of this study will be to quantify the relationship between hospital volume and patient-relevant outcomes in patients undergoing TKA.

Methods: We will include published or unpublished (cluster-) randomized controlled trials and prospective or retrospective cohort studies that involve patients with primary and/or revision TKA, report at least two different hospital volumes and report at least one patient-relevant outcome. To identify studies, we will systematically search (from inception onwards) PubMed/MEDLINE, Embase, CENTRAL, and CINAHL, as well as trial registers, conference proceedings, and reference lists. We will also contact experts in the field. Study selection and data extraction will be performed by two reviewers independently. The primary outcome will be rate of early revision. Secondary outcomes will include rate of revision > 1 year, mortality, length of stay, readmission rate, surgical complications, adverse events and health-related quality of life. We will assess the risk of bias of the included studies using ROBINS-I or the Cochrane risk of bias tool. Both a linear and a non-linear dose-response meta-analyses will be performed. We will use the GRADE approach to evaluate our confidence in the cumulative evidence. We will incorporate patients’ needs, goals and preferences into our recommendations by consulting three focus groups, each consisting of eight participants.

Discussion: The findings of our systematic review will probably be limited by the design of the included studies. We do not expect to identify any (cluster-) randomized controlled trials that meet our inclusion criteria. Therefore, the best available evidence included in our systematic review will most likely consist of cohort studies only. We anticipate that the results of this study will inform future health policy decisions in Germany regarding the minimum volume threshold for TKA.

Systematic review registration: PROSPERO CRD42019131209 (Continued on next page)
Background

Rationale

Hip and knee osteoarthritis (OA) is a common chronic condition. It was ranked as the 11th highest contributor to global disability (measured in years lived with disability) and 38th highest in disability-adjusted life years (DALYs) among 291 conditions [1]. Estimates suggest that OA will be ninth on the list of causes of DALYs in high-income countries by 2030 [2]. In addition to physical symptoms related to OA, which typically include joint pain, limitation of movement, tenderness, stiffness, crepitus, and inflammation [3], the condition is also associated with negative psychological effects. Patients suffering from OA experience more psychological distress than patients with other chronic diseases, such as diabetes [4].

Total knee arthroplasty (TKA) is the most successful treatment for end-stage knee OA, improving pain and function [5]. An international survey showed that Germany has the highest TKA rates in Europe [6]. According to the Federal Bureau of Statistics of Germany, about 191,000 primary and 25,000 secondary TKAs were performed in Germany in 2017 [7]. These figures have significantly increased since 2005 (by 48 and 56%, respectively) [7], which can mainly be attributed to the aging population. Thus, the estimates are expected to rise even more in the future. Rates for early revision, 90-day mortality and surgical complications were 3.3, 0.3 and 2.9%, respectively, in Germany between 2014 and 2016 [8]. The risk of a TKA requiring revision surgery within 10 years post-operatively is approximately 5–10%, with aseptic loosening, infection and pain being the most frequent indications for revision [9]. Early revisions present a substantial financial burden to healthcare systems [9].

In previous research, we have shown that hospital volume-outcome relationships exist in the field of surgery [10, 11]. The term refers to a relationship between the health outcome (e.g. mortality or morbidity) and hospital volume (i.e. the total numbers of a certain procedure performed per year). It is assumed that higher hospital volume results in better health outcomes. There are two hypotheses to explain this association [12]. One is that “practice makes perfect”. The underlying theory is that higher volume should result in higher proficiency and better skills and, as a consequence, in better health outcomes than lower volume. In terms of a causal relationship, high volume is the cause and better outcomes are the effect. The other is the “selective referral” hypothesis. It is based on the idea that patients are usually referred to providers known for good outcomes. Here, better outcomes are the cause and higher volume is the effect. If the “practice makes perfect” hypothesis holds true, hospitals should perform a minimum number of procedures annually to ensure reasonably good outcomes.

In Germany, minimum volume thresholds have been implemented for esophageal and pancreatic surgeries as well as liver, kidney and stem cell transplantations since 2004. Total knee replacements were added in 2006 and the care of low-birth-weight neonates in 2009. These thresholds define the minimum number of procedures a hospital needs to perform within 1 year to be able to deliver the procedure in the next year. Since January 2015, the minimum volume threshold for TKA is 50 procedures per year [13]. In hospitals adhering to minimum volume thresholds for TKA, a lower hospital mortality was observed [14]. Furthermore, lower infection rates were observed after the introduction of minimum volume thresholds for TKA [15]. Nevertheless, between 2004 and 2010, many hospitals still delivered care after having failed to reach the minimum thresholds [16] and there is an ongoing discussion on whether minimum volume thresholds truly result in better outcomes. The initial results for Germany showed only a very small effect, if any [17]. This result was later confirmed by a rapid review published by the Institute for Quality and Efficiency in Healthcare (IQWiG) [18].

To date, there is no high-quality systematic review investigating the hospital volume-outcome relationship in TKA. Existing systematic reviews have methodological flaws, for example, none of them assessed the risk of bias of the included studies [19–21]. Furthermore, these systematic reviews are probably out of date as the literature searches are older than 5 years, and it is estimated that half of the systematic reviews are out of date after 5.5 years [22]. Most importantly, it is questionable whether the statistical analyses in existing systematic reviews investigating volume-outcome relationships in general are methodologically sound. The majority of them performed meta-analyses [6, 10, 11]. Volume is frequently divided into multiple, arbitrary categories, and effect measures for meta-analyses are normally obtained by comparing the highest to the lowest volume category, irrespective of the number of volume categories and their cutoffs. This, however, can result in heterogeneous effect
measures, making any further calculations of pooled effect measures doubtful. Furthermore, this method assumes a linear relationship between hospital volume and outcome. However, a previous analysis by the IQWiG revealed a U-shaped relationship between hospital volume and insufficient mobility as an outcome in TKA [23], so that outcomes were similar for the lowest and highest volume category. Therefore, comparing these categories will tend towards no effect. To account for non-linear relationships between hospital volume and outcome, the meta-analytical approach should incorporate all volume categories and their reported effects. Non-linear dose-response meta-analytical approaches have recently been applied in other fields of medicine [24, 25].

Objectives
The objective of this study will be to quantify the relationship between hospital volume and patient-relevant outcomes in patients undergoing TKA. With our findings, we aim to inform future health policy decisions in Germany regarding the minimum volume threshold for TKA.

Methods
Eligibility criteria
- Participants: We will include studies involving patients undergoing primary and/or revision TKA that report results for TKA patients separately from other surgical procedures.
- Exposure and control: We will include studies that report outcome data for at least two different hospital volumes. Studies analysing data from one hospital only will be excluded.
- Outcomes: We will include studies reporting data for at least one patient-relevant outcome. The primary outcome of this systematic review is the rate of early revision. A list of potential secondary outcomes can be found under Outcomes and prioritization.
- Study design: We will include all published or unpublished (cluster-) randomized controlled trials (RCTs) and prospective or retrospective cohort studies. Modelling studies will be excluded.

We will include studies using volume categories, such as “high” and “low”, as well as studies using continuous values. We will only look at hospital volume, not at surgeon volume.

Information sources
We will search the following electronic databases:
- MEDLINE (via PubMed): inception to present
- EMBASE (via EMBASE): inception to present
- CENTRAL (via Cochrane Library): inception to present
- CINAHL (via EBSCO): inception to present

We will search the following trial registries:
- ClinicalTrials.gov
- German Clinical Study Register (DRKS)
- International Clinical Trials Registry Platform (ICTRP)

We will search manually for additional studies by cross-checking the reference lists of all included primary studies and of relevant systematic reviews. Furthermore, we will contact experts in the field for additional studies, i.e. the corresponding authors of relevant systematic reviews.

Finally, we will conduct a hand search of conference proceedings of the following conferences:
- International Society of Arthroscopy, Knee Surgery and Orthopaedic Sports Medicine (ISAKOS)
- American Academy of Orthopaedic Surgeons (AAOS)
- European Knee Society (EKS)
- Pan Pacific Orthopaedic Congress
- Société Internationale de Chirurgie Orthopédique et de Traumatologie (SICOT)
- American Orthopaedic Society for Sports Medicine (AOSSM)

For each potentially relevant conference abstract, we will request the study report/full-text article from the authors. We will only include studies for which a published or unpublished study report/full text is available so that we can adequately perform risk-of-bias assessment.

Search strategy
The search strategy will be developed by the research team in collaboration with an experienced librarian and checked against the Peer Review of Electronic Search Strategies (PRESS) guideline [26]. We will apply no restrictions regarding language, publication data and publication status. A draft of the PubMed search strategy is presented below:

("Hospitals, High-Volume"[Mesh] OR “Hospitals, Low-Volume”[Mesh] OR regionali*[tiab] OR centrali*-[tiab] OR decentrali*[tiab] OR caseload [tiab] OR workload [tiab] OR “volume-outcome”[tiab] OR "hospital volume"[tiab] OR “hospital volumes”[tiab] OR “hospital size”[tiab] OR “clinic size”[tiab] OR “clinic size”[tiab] OR...
“center volume”[tiab] OR “center volumes”[tiab] OR “center size”[tiab] OR “centre volume”[tiab] OR “centre size”[tiab] OR “provider volume”[tiab] OR “patient volume”[tiab] OR “patient volumes”[tiab] OR “doctor volumes”[tiab] OR “procedure volume”[tiab] OR “procedural volume”[tiab] OR “procedural volumes”[tiab] OR “procedural volume”[tiab] OR “procedural volumes”[tiab] OR “procedure volume”[tiab] OR “procedural volume”[tiab] OR “treatment volume”[tiab] OR “treatment volume”[tiab] OR “treatment volume”[tiab] OR “facility volume”[tiab] OR “facility volumes”[tiab] OR “facility volume”[tiab] OR “treatment volume”[tiab] OR “treatment volume”[tiab] OR “treatment volume”[tiab] OR “provider volume”[tiab] OR “doctor volumes”[tiab] AND (“Knee”[Mesh] OR “Arthroplasty, Replacement, Knee”[Mesh] OR “Osteoarthritis, Knee”[Mesh] OR arthroplasty [tiab] OR TKA [tiab] OR osteoarthritis [tiab])

Data management
All potentially relevant hits will be imported into EndNote (Clarivate Analytics, version X9.1). Duplicate records will be removed prior to the selection process.

Selection process
Two reviewers will independently screen the titles and abstracts of all unique records using EndNote. For all records deemed by at least one reviewer to be potentially relevant, we will retrieve the full text. Full-text articles will then be reviewed by two reviewers independently. At this stage, both reviewers must consider an article eligible for it to be included. Discrepancies will be resolved by discussion, involving a third reviewer if necessary. In case of any uncertainties, we will contact the authors of the primary studies via email.

Data collection process
A standardized data extraction tool will be developed in Excel and calibrated with the team. Using a random sample of five of the included studies, the data extraction form will be pilot-tested, and revised as necessary. We will then successively test the revised data extraction sheet using further randomly selected studies. Data extraction will begin as soon as high inter-rater reliability (kappa statistic ≥ 0.60) has been achieved [27]. Two review authors will independently perform data extraction of the included studies using the standardized and piloted data collection form. Then, both reviewers will check each other’s versions for completeness and accuracy. Discrepancies will be resolved by discussion, involving a third reviewer if necessary. In case of any uncertainties or missing data, we will contact the authors of the primary studies via email.

Data items
We will extract data on the following items:

- Sample size (number of patients, number of TKA procedures)
- Hospital and patient eligibility criteria
- Hospital characteristics (size, degree of specialisation, location, ownership)
- Surgeon volume (e.g. annual number of TKA procedures per surgeon)
- Surgeon experience (e.g. in postgraduate years)
- Year(s) of data collection
- Country/region
- Data source (clinical vs. administrative)
- Database/registry (if any)
- Definition of hospital volume
- Categorization of exposure variables (i.e. thresholds, if any)
- Procedure characteristics (e.g. types of prostheses)
- Outcomes
- Effect measures (unadjusted and adjusted) with their confidence intervals and/or p values
- Statistical models
- Adjusting variables

This choice includes all relevant information suggested to be taken into consideration when analysing volume-outcome analyses [28].

Outcomes and prioritization
Primary outcome: Rate of early revision (i.e. rate of revision at 1 year)
Secondary outcomes might include, but are not limited to, the following outcomes (each as defined by the study authors):

- Mortality (hospital mortality, 30-day mortality, 90-day mortality)
- Patient survival
- Length of stay
- Readmission rate
- Surgical complications
- Rate of revision > 1 year, e.g. at 5 years
- Implant survival
- Adverse events, such as (wound) infection, pneumonia, pulmonary embolism, deep vein thrombosis or vascular complications
- Health-related quality of life (e.g. measured with the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) [29])

Risk of bias in individual studies
We will use the Cochrane ROBINS-I tool (Risk Of Bias In Non-randomized Studies-of Interventions) to assess the risk of bias of observational studies [30]. This tool can also be used to evaluate observational studies in which the intervention is an exposure (i.e. risk factor–high volume). ROBINS-I assesses baseline and time-varying confounding, co-interventions, selection bias,
hospital volume as a categorical variable. The majority of studies treat hospital volume can be analysed either as a continuous or as a categorical variable. The methods by Greenland and Longnecker [33]. We will choose the model with the lowest deviance. All hospital volume categories will be included to model the association between hospital volume and outcomes. When the lowest category is not the reference category, odds ratios will be converted using accepted methods [35]. Finally, the difference between the linear and non-linear models will be examined by a likelihood ratio test [34].

Hospital volume can be defined based on different periods. For meta-analyses, it is important to standardize hospital volume so that the exposure in all studies corresponds to the same period. Thus, we will standardize all volume measures to a 1-year period. For example, for a study reporting hospital volume for a 5-year period, we will divide all raw numbers by 5 and recalculate effect measures with 95% confidence intervals. This assumes that the volume-outcome effect is constant, i.e. not dependent on the study year. This can be expected to yield valid numbers, because TKA is a very frequent procedure and has been performed since many decades.

If more than one effect estimate is reported, we will choose the model with the greatest degree of control for potential confounding. We will calculate pooled odds ratios, mean differences or, if necessary, standardized mean differences.

We will conduct three sensitivity analyses. In the first sensitivity analysis, we will conduct a univariate inverse-variance random-effects meta-analysis (highest vs. lowest volume category), instead of dose-response meta-analysis. We will use the Paule and Mandel heterogeneity variance estimator and modified Hartung-Knapp confidence intervals for the pooled estimates [36, 37]. Beta-binomial models (random-effects model) will be computed for rare events, such as mortality [38]. In the second sensitivity analysis, we will only include studies that report values adjusted at least for age, gender and comorbidity. In the third sensitivity analysis, we will only include studies that report values adjusted at least for age, gender, comorbidity and surgeon volume to account for the role of surgeon volume on the outcome.

Subgroup analyses will be performed for each outcome by grouping the studies according to the following variables:

data synthesis

Hospital volume can be analysed either as a continuous or as a categorical variable. The majority of studies treat hospital volume as a categorical variable [10, 11, 28].

Prior to conducting the meta-analysis, we will investigate clinical and methodological heterogeneity among the studies and will only include studies in the meta-analysis that are sufficiently homogenous. Furthermore, we will only pool outcome data if measured at comparable time points.

Our methodological approach is a dose-response meta-analysis based on best adjusted effect estimates. The first analysis will assume a linear dose-response relationship, while the second analysis will assume a non-linear relationship. In the first stage, we will estimate a dose-response curve (here, hospital volume-outcome curve) for each study across hospital volume values observed in the whole dataset. In the second stage, these curves will be pooled into an overall hospital volume-outcome curve. The dose-response analysis will follow the methods [34]. We will calculate study-specific slopes (linear trends) and 95% confidence intervals from the natural logs of the reported effect measures and confidence intervals across hospital volume categories, taking the correlations between odds ratios into account. In cases where the reference category is not the lowest category, we will first try to recalculate data in such a way that the lowest category will be the reference category. In cases where this is not possible, we will exclude the categories below the reference category for the linear dose-response analysis. For studies reporting ranges of hospital volumes, the midpoint of the lower and upper cut-off will be assigned to each category. When upper and lower categories are open-ended or have extreme upper or lower values, the width of the adjacent category will be used to calculate an upper or lower bound. When authors report the median or mean hospital volume per category, this will be used to assign the corresponding odds ratio for each study.
Heterogeneity will be assessed by the Q test and $I^2$ statistic [39].

All analyses will be performed with R using the metafor and dosresmeta packages [40, 41].

**Meta-bias(es)**

For the univariate inverse-variance random-effects meta-analysis, we will assess publication bias by visually inspecting funnel plots for asymmetry. Following the recommendations by Sterne et al. [42], we will only test for funnel plot asymmetry in meta-analyses including at least 10 studies. As empirical research found that agreement between different tests of publication bias is relatively low [43], we will apply two tests, namely Egger’s test [44] and Begg’s test [45]. A $p$ value < 0.1 will be considered statistically significant because the statistical power of the publication bias tests is generally low [44, 45].

**Confidence in cumulative evidence**

Confidence in the cumulative evidence will be evaluated using the Grading of Recommendations, Assessment, Development, and Evaluation (GRADE) approach [46]. The GRADE approach uses five considerations (study limitations, consistency of effect, imprecision, indirectness and publication bias) to assess the quality of the body of evidence for specific outcomes. Although GRADE has originally been developed for clinical questions, it can also be applied to public health or health system questions [47]. Assessment will be performed by two reviewers independently using the GRADEpro GDT software [48]. Discrepancies will be resolved by discussion involving a third reviewer if necessary. Summary of findings tables will be prepared for the seven most important outcomes.

**Patient involvement in formulating recommendations**

Minimum volume thresholds do not only affect hospitals, but might also have consequences for patients (e.g., longer travel times). Since this systematic review aims at informing future health policy decisions in Germany regarding the minimum volume threshold for TKA, we will incorporate patients’ needs, goals and preferences into our recommendations.

More specifically, we will establish three focus groups, each consisting of eight participants who are heterogeneous in terms of age, gender, socioeconomic status and whether they have previously undergone knee arthroplasty. Participants will be recruited through relevant networks, including the Witten/Herdecke University Hospital in Cologne-Merheim. We will obtain written informed consent from all participants prior to the conduct of the focus groups. The first focus group is used to investigate prior assumptions and beliefs on the existence of a hospital volume-outcome relationship regarding TKA. Furthermore, patients’ willingness to travel longer distances for better health outcomes will be discussed. The other two focus groups will meet after completion of the systematic review to discuss the review results and potential consequences. One of those focus groups will involve participants only from urban areas, and the other participants only from rural areas, who are more likely to be affected by minimum volume thresholds. All discussions will be recorded and transcribed for qualitative content analysis according to Mayring [49] using the software MAXQDA (VERBI Software, 2016). For this part of our study, ethics approval was obtained from the ethics committee of Witten/Herdecke University.

Furthermore, our team will involve a patient representative with knowledge about minimum volume thresholds. He/she will be invited to take part in all focus groups and to comment on the manuscript for the completed systematic review.

**Plan for documenting important protocol amendments**

Important protocol amendments will be documented in PROSPERO as well as in the review publication.

**Discussion**

With this systematic review, we aim to inform future health policy decisions in Germany. As we will include studies dealing with populations from any country and continent, it is likely that our findings will also be applicable to healthcare settings outside Germany and Europe.

The findings of our systematic review will probably be limited by the study designs of the included studies. Although one could theoretically randomize patients to high- or low-volume hospitals, this is not likely to be acceptable from a patient perspective and makes the conception of (cluster-) RCTs addressing hospital volume-outcome relationships nearly impossible. Previous volume-outcome analyses were solely based on cohort studies [28], and we do not expect to identify any (cluster-) RCTs that meet our inclusion criteria, either. Therefore, the best available evidence included in our systematic review will most likely consist of cohort studies [20, 28].

**Abbreviations**

DALYs: Disability-adjusted life years; GRADE: Grading of Recommendation, Assessment, Development, and Evaluation; IQWiG: Institute for Quality and Efficiency in Healthcare; OA: Osteoarthritis; RCT: Randomized controlled trial; TKA: Total knee arthroplasty
Acknowledgments
Not applicable.

Authors’ contributions
DP, TM and TR drafted the manuscript. All authors have critically reviewed the manuscript and have approved the final version. DP acts as the guarantor of the review.

Funding
This project is funded by the Federal Ministry of Education and Research of Germany-BMBF (reference number 01KG1805). The funder had no role in developing the protocol and will not have any role in the conduct of the systematic review or focus groups or the interpretation and dissemination of its findings.

Availability of data and materials
The datasets used and/or analysed during the current study are available from the corresponding author on reasonable request.

Availability of data and materials
The datasets used and/or analysed during the current study are available from the corresponding author on reasonable request.

The datasets used and/or analysed during the current study are available from the corresponding author on reasonable request.

Consent for publication
For the focus groups, ethics approval was obtained from the ethics committee of Witten/Herdecke University (reference number 54/2019). Written informed consent will be obtained from the participants prior to the conduct of the focus groups.

Consent for publication
For the focus groups, ethics approval was obtained from the ethics committee of Witten/Herdecke University (reference number 54/2019). Written informed consent will be obtained from the participants prior to the conduct of the focus groups.

Ethics approval and consent to participate
For the focus groups, ethics approval was obtained from the ethics committee of Witten/Herdecke University (reference number 54/2019). Written informed consent will be obtained from the participants prior to the conduct of the focus groups.

Consent for publication
Not applicable.

Competing interests
The authors declare that they have no competing interests.

Author details
1Institute for Research in Operative Medicine, Witten/Herdecke University, Ostmerheimer Str. 200, 51109 Cologne, Germany. 2Department of Trauma Surgery and Orthopaedics, Lahn-Dill-Kliniken Dillenburg, Dillenburg, Germany. 3Department of Health, University of Witten/Herdecke, Witten, Germany.

Received: 17 April 2019 Accepted: 13 February 2020
Published online: 20 February 2020

References
1. Cross M, Smith E, Hoy D, Nolte S, Ackerman I, Fransen M, et al. The global burden of hip and knee osteoarthritis: estimates from the global burden of disease 2010 study. Ann Rheum Dis. 2014;73(7):1323–30.
2. Mathers CD, Loncar D. Projections of global mortality and burden of disease from 2002 to 2030. PLOS Med. 2006;3(11):e442.
3. EULAR study group on OA 2015. https://www.eular.org/myUploadData/Files/OA-Research%20Agenda-final.pdf. Accessed 14 April 2019.
4. Penninx BW, Beekman AT, Ormel J, Kriegsman DM, Boeke AJ, van Eijk JT, et al. Psychological status among elderly people with chronic diseases: does type of disease play a part? J Psychosom Res. 1996;40(5):521–34.
5. Memtsoudis SG, Gonzalez Dela Valle A, Besculides MC, Gaber L, Sculco TP. In-hospital complications and mortality of unilateral, bilateral, and revision knee arthroplasty. J Bone Joint Surg Am. 2010;92(3):629–38.
6. Kurtz SM, Ong KL, Lau E, Widmer M, Maravic M, Gomez-Barrena E, et al. Psychological status among elderly people with chronic diseases: does type of disease play a part? J Psychosom Res. 1996;40(5):521–34.
7. Ministério da Saúde. Avaliação do desempenho hospitalar de cirurgias ortopédicas: protocolo. Brasília. 2014;1(55):e18.
8. The Cochrane Collaboration. The Cochrane Database of Systematic Reviews: 2010 Issue 1. 2010. CD001987.
9. Higgins JPT, Altman DG, Gøtzsche PC, Jüni P, Moher D, Oxman AD, et al. ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions. BMJ. 2016;355:i4919.
10. Pieper D, Mathes T, Neugebauer E, Eikemann M. State of evidence on the relationship between high-volume hospitals and outcomes in surgery: a systematic review of systematic reviews. J Am Coll Surg. 2013;216(1):1015–25 e18.
11. Morche J, Mathes T, Pieper D. Relationship between surgeon volume and outcomes: a systematic review of systematic reviews. Syst Rev. 2016;5(1):204.
12. Luft HS, Hunt SS, Maerki SC. The volume-outcome relationship: practice-makes-perfect or selective-referral patterns? Health Serv Rev. 1987;22(2):157–82.
13. The Federal Joint Committee (G-BA). Regelungen des Gemeinsamen Bundesausschusses gemäß § 138b Absatz 1 Satz 1 Nummer 2 SGB V für nach § 108 SGB V zugelassene Krankenhäuser (Mindestmengenregelungen, MmR). https://www.g-ba.de/richtlinien/S/. Accessed 14 April 2019.
14. Nimptsch U, Peschke D, Mansky T. Minimum caseload requirements and in-hospital mortality: observational study using nationwide hospital discharge data from 2006 to 2013. Gesundheitswesen. 2016;79(10):823–34.
15. Ohmann C, Verde PE, Blum K, Fischer B, de Cruppe W, Geraedts M. Two short-term outcomes after instituting a national regulation regarding minimum procedural-volumes for total knee replacement. J Bone Joint Surg Am. 2010;92(3):629–38.
16. de Cruppe W, Malik M, Geraedts M. Achieving minimum caseload requirements: an analysis of hospital quality control reports from 2004-2010. Dtsch Arztebl Internat. 2014;111(33-34):549–55.
17. Geraedts M, Cruppel WD, Blum K, Ohmann C. Umsetzung und Auswirkungen der Mindestmengen. Dtsch Arztebl International. 2008;105(51-52):890–6.
18. Stengel D. Auswirkungen der Regelungen über Mindestmengen. Unfallchirurg. 2012;115(9):840–3.
19. Marlow NE, Barraclough B, Collier NA, Dickinson IC, Fawcett J, Graham JC, et al. Centralization and the relationship between volume and outcome in knee arthroplasty procedures. ANZ J Surg. 2010;80(4):234–41.
20. Stengel D, Ekkernkamp A, Dettoni J, Hansen B, Stimbert H, et al. Minimum caseload requirements and in-hospital mortality: observational study using nationwide hospital discharge data from 2006 to 2013. Gesundheitswesen. 2016;79(10):823–34.
21. Critchley RJ, Baker PN, Deehan DJ. Does surgical volume affect outcome after primary and revision knee arthroplasty? A systematic review of the literature. Knee. 2012;19(5):513–8.
22. Shojania KG, Sampson M, Ansari MT, Ji J, Doucette S, Moher D. How quickly do systematic reviews go out of date? A survival analysis. Ann Intern Med. 2007;147(4):224–33.
23. Schröder P, Grouven U, Bender R. Kann Mindestmengen für Knieprothesen anhand von Routinedaten errechnet werden? Orthopäde. 2007;36(6):570–6.
24. Aune D, Sen A, Prasad M, Norat T, Janszky I, Tonstad S, et al. BMI and all cause mortality: systematic review and non-linear dose-response meta-analysis of 230 cohort studies with 3.74 million deaths among 30.3 million participants. BMJ. 2016;353:i2156.
25. Patra J, Bakker R, Irving H, Jaddoe VW, Malini S, Rehm J. Dose-response relationship between alcohol consumption before and during pregnancy and the risks of low birthweight, preterm birth and small for gestational age (SGA)—a systematic review and meta-analyses. BJOG. 2011;118(12):1411–21.
26. McGowan J, Sampson M, Sabwede DM, Cogo E, Forster V, Leefebvre C. PRESS peer review of electronic search strategies: 2015 guideline statement. J Clin Epi. 2016;75:40–6.
27. Landis JR, Koch GG. The measurement of observer agreement for categorical data. Biometrics. 1977;33(1):159–74.
28. Halm EA, Lee C, Chassin MR. Is volume related to outcome in health care? A systematic review and methodologic critique of the literature. Ann Intern Med. 2002;137(6):511–20.
29. Bellamy N, Buchanan WW, Goldsmith CH, Campbell J, Stitt LW. Validation study of WOMAC: a health status instrument for measuring clinically important patient relevant outcomes to antirheumatic drug therapy in patients with osteoarthritis of the hip or knee. J Rheumatol. 1988;15(2):1833–40.
30. Sterne JAC, Hernán MA, Reeves BC, Savovic J, Berkman ND, Viswanathan M, et al. ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions. BMJ. 2016;355:i4919.
31. Higgins JPT, Altman DG, Gøtzsche PC, Jüni P, Moher D, Oxman AD, et al. The Cochrane Collaboration’s tool for assessing risk of bias in randomised trials. BMJ. 2011;343:d5928.
32. Higgins JPT, Savović J, Page MJ, Hróbjartsson A, Boutron I, Reeves B, Eldridge S. A revised tool for assessing risk of bias in randomized trials. In: JMJ C, Boutron I, Welch V, editors. Cochrane Methods: Cochrane Database of Systematic Reviews; 2016.
33. Greenland S, Longnecker MP. Methods for trend estimation from summarized dose-response data, with applications to meta-analysis. Am J Epidemiol. 1992;135(1):1301–9.
34. Bagnardi V, Zambon A, Quatto P, Corrao G. Flexible meta-regression functions for modeling aggregate dose-response data, with an application to alcohol and mortality. Am J Epidemiol. 2004;159(11):1077–86.
35. Hamling J, Lee P, Weikusat R, Amruth M. Facilitating meta-analyses by deriving relative effect and precision estimates for alternative comparisons from a set of estimates presented by exposure level or disease category. Stat Med. 2008;27(7):954–70.
36. IntHout J, Ioannidis JP, Borm GF. The Hartung-Knapp-Sidik-Jonkman method for random effects meta-analysis is straightforward and considerably outperforms the standard DerSimonian-Laird method. BMC Med Res Methodol. 2014;14:25.
37. Veroniki AA, Jackson D, Viechtbauer W, Bender R, Bowden J, Knapp G, et al. Methods to estimate the between-study variance and its uncertainty in meta-analysis. Res Synth Methods. 2016;7(1):55–79.
38. Ma Y, Chu H, Mazumdar M. Meta-analysis of proportions of rare events—a comparison of exact likelihood methods with robust variance estimation. Commun Stat Simul C. 2016;45(8):3036–52.
39. Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med. 2002;21(11):1539–58.
40. Viechtbauer W. The metafor package: a meta-analysis package for R 2017. http://www.metafor-project.org/doku.php. Accessed 14 Apr 2019.
41. Crippa A, Orsini N. Multivariate dose-response meta-analysis: the dosresmeta R Package. J Stat Softw. 2016;72(1):1–15.
42. Sterne JAC, Sutton AJ, Ioannidis JPA, Terrin N, Jones DR, Lau J, et al. Recommendations for examining and interpreting funnel plot asymmetry in meta-analyses of randomised controlled trials. BMJ. 2011;343:d4002.
43. Lin L, Chu H, Murad MH, Hong C, Qu Z, Cole SR, et al. Empirical comparison of publication bias tests in meta-analysis. J Gen Intern Med. 2018;33(8):1260–7.
44. Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997;315(7109):629–34.
45. Begg CB, Mazumdar M. Operating characteristics of a rank correlation test for publication bias. Biometrics. 1994;50(4):1088–101.
46. Brozek JL, Akl EA, Compalati E, Kreis J, Terracciano L, Fiocchi A, et al. Grading quality of evidence and strength of recommendations in clinical practice guidelines part 3 of 3. The GRADE approach to developing recommendations. Allergy. 2011;66(5):588–95.
47. The GRADE Working Group. GRADE handbook for grading quality of evidence and strength of recommendations. https://gdt.gradepro.org/app/handbook/handbook.html. Accessed 14 Apr 2019.
48. GRADEPro GDT: GRADEPro Guideline Development Tool [Software]. McMaster University, 2015 (developed by Evidence Prime, Inc.). Available from gradepro.org.
49. Mayring P, editor. Qualitative Inhaltsanalyse. Grundlagen und Techniken. Weinheim: Juventa; 2010.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.